Search

Your search keyword '"Vesicular stomatitis Indiana virus drug effects"' showing total 1,039 results

Search Constraints

Start Over You searched for: Descriptor "Vesicular stomatitis Indiana virus drug effects" Remove constraint Descriptor: "Vesicular stomatitis Indiana virus drug effects"
1,039 results on '"Vesicular stomatitis Indiana virus drug effects"'

Search Results

1. Vesicular Stomatitis Virus as a Platform for Protease Activity Measurements.

2. Octyl itaconate enhances VSVΔ51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways.

3. Mechanisms of anti-vesicular stomatitis virus activity of deazaneplanocin and its 3-brominated analogs.

4. Validation of a binary ethylenimine (BEI) inactivation procedure for biosafety treatment of foot-and-mouth disease viruses (FMDV), vesicular stomatitis viruses (VSV), and swine vesicular disease virus (SVDV).

5. High Throughput Screening of FDA-Approved Drug Library Reveals the Compounds that Promote IRF3-Mediated Pro-Apoptotic Pathway Inhibit Virus Replication.

6. Vesicular Stomatitis Virus Transcription Is Inhibited by TRIM69 in the Interferon-Induced Antiviral State.

7. Expression and characterization of albumin fusion protein canine IFNγ-CSA in baculovirus-insect cell expression system.

8. Vesiculopolins, a New Class of Anti-Vesiculoviral Compounds, Inhibit Transcription Initiation of Vesiculoviruses.

9. Social evolution of innate immunity evasion in a virus.

10. Neuralized E3 Ubiquitin Protein Ligase 3 Is an Inducible Antiviral Effector That Inhibits Hepatitis C Virus Assembly by Targeting Viral E1 Glycoprotein.

11. Secretome Screening Reveals Fibroblast Growth Factors as Novel Inhibitors of Viral Replication.

12. Porcine monocyte-derived dendritic cells can be differentially activated by vesicular stomatitis virus and its matrix protein mutants.

13. Large-scale purification of high purity α1-antitrypsin from Cohn Fraction IV with virus inactivation by solvent/detergent and dry-heat treatment.

14. Dengue virus induced changes in Ca 2+ homeostasis in human hepatic cells that favor the viral replicative cycle.

15. Establishing a safe, rapid, convenient and low-cost antiviral assay of interferon bioactivity based on recombinant VSV expressing GFP.

16. Virtual screening, synthesis and biological evaluation of DNA intercalating antiviral agents.

17. Virus-Triggered ATP Release Limits Viral Replication through Facilitating IFN-β Production in a P2X7-Dependent Manner.

18. Activation of Nrf2 Signaling Augments Vesicular Stomatitis Virus Oncolysis via Autophagy-Driven Suppression of Antiviral Immunity.

19. Environmental Stress Causes Lethal Neuro-Trauma during Asymptomatic Viral Infections.

20. Vesicular stomatitis virus N protein-specific single-domain antibody fragments inhibit replication.

21. Curcumin inhibits Zika and chikungunya virus infection by inhibiting cell binding.

22. Mechanisms of Vesicular Stomatitis Virus Inactivation by Protoporphyrin IX, Zinc-Protoporphyrin IX, and Mesoporphyrin IX.

23. Inactivation of viruses by pasteurization at 60 °C for 10 h with and without 40% glucose as stabilizer during a new manufacturing process of α2-Macroglobulin from Cohn Fraction IV.

24. Quinoxaline-based inhibitors of Ebola and Marburg VP40 egress.

25. Limited Effects of Type I Interferons on Kyasanur Forest Disease Virus in Cell Culture.

26. Migration of Nucleocapsids in Vesicular Stomatitis Virus-Infected Cells Is Dependent on both Microtubules and Actin Filaments.

27. First-in-class small molecule potentiators of cancer virotherapy.

28. Characterization of Glycoprotein-Mediated Entry of Severe Fever with Thrombocytopenia Syndrome Virus.

29. A "building block" approach to the new influenza A virus entry inhibitors with reduced cellular toxicities.

30. Inhibition of EHMT2 Induces a Robust Antiviral Response Against Foot-and-Mouth Disease and Vesicular Stomatitis Virus Infections in Bovine Cells.

31. Curcumin and Boswellia serrata gum resin extract inhibit chikungunya and vesicular stomatitis virus infections in vitro.

32. Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1.

33. Fluvastatin delays propagation of viral infection in isolated rat FDB myofibers but does not affect exocytic membrane trafficking.

34. Memory Antitumor T-Cells Resist Inhibition by Immune Suppressor Cells.

35. OBTAINING OF THE TRANSGENIC HELIANTHUS TUBEROSUS L. PLANTS, CALLUS AND "HAIRY" ROOT CULTURES ABLE TO EXPRESS THE RECOMBINANT HUMAN INTERFERON ALPHA-2b GENE.

36. [A PERSPECTIVE CULTURAL MODEL FOR CONTROL OF BIOLOGICAL ACTIVITY OF HUMAN INTERFERONS].

37. Cloning and expression of mink (Neovison vison) interferon-γ gene and development of an antiviral assay.

38. Fine Tuning of a Type 1 Interferon Antagonist.

39. Characterization of the biological activities and physicochemical characteristics of recombinant bovine interferon-α₁₄.

40. Synthesis and quantitative structure-activity relationship (QSAR) analysis of some novel oxadiazolo[3,4-d]pyrimidine nucleosides derivatives as antiviral agents.

41. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry.

42. Cloning, expression and antiviral bioactivity of red-crowned crane interferon-α.

43. Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-κB-dependent autophagy.

44. Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo.

45. Lithium attenuates IFN-β production and antiviral response via inhibition of TANK-binding kinase 1 kinase activity.

46. In vitro inhibition of vesicular stomatitis virus replication by purified porcine Mx1 protein fused to HIV-1 Tat protein transduction domain (PTD).

47. Interferon alpha-armed nanoparticles trigger rapid and sustained STAT1-dependent anti-viral cellular responses.

48. Stability and inactivation of vesicular stomatitis virus, a prototype rhabdovirus.

49. Optimization of soluble human interferon-γ production in Escherichia coli using SUMO fusion partner.

50. Creation of transgenic Brassica napus L. plants expressing human alpha 2b interferon gene.

Catalog

Books, media, physical & digital resources